Diabetic vascular complications

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 9-10, 1997, Pages 770-775

  Cooper, Mark E ^a   Gilbert, Richard E ^a   Jerums, George ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aminoguanidine; Diabetes; Glycation; Hypertension; Nephropathy; Retinopathy; Vasculopathy

Indexed keywords

AMINOGUANIDINE; EPIDERMAL GROWTH FACTOR; POLYOL; PROTEIN KINASE C; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; EXTRACELLULAR MATRIX; GLUCOSE METABOLISM; GLYCATION; HEMODYNAMICS; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PERIPHERAL VASCULAR DISEASE;

EID: 0030983807     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb02130.x     Document Type: Conference Paper

References (65)

1. Clark CJ, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N. Engl. J. Med. 1995; 332: 1210-17.
2. Mogensen CE. Glomerular hyperfiltration in human diabetes. Diabetes Care 1994; 17: 770-5.
3. Brownlee M, Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994; 43: 836-41.
4. Yamada H, Miyata S, Igaki N et al. Increase in 3-deoxyglucosone levels in diabetic rat plasma. Specific in vivo determination of intermediate in advanced Maillard reaction. J. Biol. Chem. 1994; 269: 20 275-80.
5. Pongor S, Ulrich P, Bencsath F, Cerami A. Aging of proteins: Isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc. Natl Acad. Sci. USA 1989; 81: 2684-8.
6. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J. Clin. Invest. 1990; 85: 380-4.
7. Fu MX, Knecht KJ, Thorpe SK, Baynes JW. Role of oxygen in crosslinking and chemical modification of collagen by glucose. Diabetes 1992; 2: 42-8.
8. Soulis T, Cooper M, Vranes D, Bucula R, Jerums G. The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int. 1996; 50: 627-34.
9. Rumble JR, Cooper ME, Soulis T et al. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J. Clin. Invest. 1997; 99: 1016-27.
10. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986; 232: 1629-32.
11. Nicholls K, Mandel T. Advanced glycosylation end products in experimental murine diabetic nephropathy: Effect of islet grafting and of aminoguanidine. Lab. Invest. 1989; 60: 486-9.
12. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-34.
13. Hammes H, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl Acad. Sci. USA 1991; 88: 11 555-8.
14. Yagihashi S, Kamijo M, Ido Y, Mirrlees D. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy: Ultrastructural and morphometric studies of sural nerve in streptozotocin-induced diabetic rats. Diabetes 1990; 39: 690-6.
15. Makita Z, Vlassara H, Rayfield E et al. Hemoglobin-AGE: A circulating marker of advanced glycosylation. Science 1992; 258: 651-3.
16. Wolffenbuttel BH, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996; 347: 513-15.
17. Kochakian M, Manjula B, Egan J. Chronic dosing with aminoguanidine and novel advanced glycosylation end product formation inhibitors ameliorates cross-linking of tail tendon collagen in streptozotocin-induced diabetic rats. Diabetes 1996; 45: 1694-700.
18. Vasan S, Zhang X, Zhang X et al. An agent cleaving glucose-derived protein cross-links in vitro and in vivo. Nature 1996; 382: 275-8.
19. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation. Proc. Natl Acad. Sci. USA 1992; 89: 11 059-63.
20. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258: 607-14.
21. Lynch JJ, Ferro TJ, Blumenstock FA, Brockenauer AM, Malik AB. Increased endothelial albumin permeability mediated by protein kinase C activation. J. Clin. Invest. 1990; 85: 1991-8.
22. Craven PA, Studer RK, Negrete H, DeRubertis FR. Protein kinase C in diabetic nephropathy. J. Diabetes Comp. 1995; 9: 241-5.
23. Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-31.
24. Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: Neuropathy, pathogenetic considerations. Diabetes Care 1992; 15: 1902-25.
25. Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am. J. Kidney Dis. 1995; 26: 875-88.
26. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc. Natl Acad. Sci. USA 1985; 82: 5963-7.
27. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am. J. Physiol. 1993; 265: F477-86.
28. Dzau V. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988; 77 (Suppl. 1): 1-4.
29. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 1996; 49: 578-97.
30. Campbell DJ. Circulating and tissue angiotensin systems. J. Clin. Invest. 1987; 79: 1-6.
31. Berka JL, Stubbs AJ, Wang DZM et al. Renin containing Müller cells of the retina display endocrine features. Invest. Ophthalmol. Vis. Sci. 1995; 36: 1450-8.
32. Ortola FV, Ballerman BJ, Anderson S, Mendez RE, Brenner BM. Elevated plasma atrial natriuretic peptide levels in diabetic rats. J. Clin. Invest. 1987; 80: 670-4.
33. Komers R, Cooper ME. Acute renal haemodynamic effects of angiotensin converting enzyme inhibition in diabetic hyperfiltration: The role of kinins. Am. J. Physiol. 1995; 268: F588-94.
34. Fukui M, Nakamura T, Ebihara I et al. Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J. Lab. Clin. Med. 1993; 122: 149-56.
35. Gilbert RE, Jerums G, Cooper ME. Extracellular matrix, growth factors and their interactions in the pathogenesis of diabetic kidney disease. Nephrology 1996; 2: 291-303.
36. Gilbert RE, McNally PG, Cox A et al. SPARC gene expression is reduced in early diabetes related kidney growth. Kidney Int. 1995; 48: 1216-25.
37. Wu L, Roe C, Cox A, Dziadek M, Cooper ME, Gilbert RE. Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int. 1997; 51: 1553-67.
38. McLennan SV, Fisher EJ, Yue DK, Turtle JR. High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 1994; 43: 1041-5.
39. Nakamura T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H. Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Renal Physiol. Biochem. 1994; 17: 316-25.
40. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl Acad. Sci. USA 1993; 90: 1814-18.
41. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 1994; 331: 1480-7.
42. Border WA, Brees D, Noble NA. Transforming growth factor-beta and extracellular matrix deposition in the kidney. Contrib. Nephrol. 1994; 107: 140-5.
43. Bach LA, Jerums G. Effect of puberty on initial kidney growth and rise in kidney IGF-1 in diabetic rats. Diabetes 1990; 39: 557-62.
44. Flyvbjerg A, Thorlacius-Ussing O, Naeraa R, Ingerslev J, Orskov H. Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomised rats. Diabetologia 1988; 31: 310-14.
45. Gilbert RE, Cox A, McNally PG et al. Increased epidermal growth factor in experimental diabetes related kidney growth. Diabetologia 1997 (in press).
46. Nakamura T, Fukui M, Ebihara I et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993; 42: 450-6.
47. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-46.
48. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin H increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25: 913-17.
49. Ballerman BJ, Skorecki KL, Brenner BM. Reduced glomerular angiotensin II receptor density in early untreated diabetes mellitus in the rat. Am. J. Physiol 1984; 247: F110-16.
50. Youssef S, Soulis T, Cooper ME. Increased binding of advanced glycated products in the diabetic kidney. Diabetologia 1996; 39 (Suppl. 1): A23.
51. Johnston CI. Angiotensin receptor antagonists: Focus on losartan. Lancet 1995; 346: 1403-7.
52. Li Y, Mitsuhashi T, Wojciechowicz D et al. Molecular identity and distribution of advanced glycation endproducts receptors: Relationship of p60 to OST-48 and p90-80K-H membrane proteins. Proc. Natl Acad. Sci. USA 1996; 93: 11 047-52.
53. Neeper M, Schmidt A, Brett J et al. Cloning and expression of a cell surface receptor for advanced glycation end products of proteins. J. Biol. Chem. 1992; 267: 14998-15004.
54. Schmidt AM, Hasu M, Popov D et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl Acad. Sci. USA 1994; 91: 8807-11.
55. Wautier JL, Zoukourian C, Chappey O et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 1996; 97: 238-43.
56. Soulis T, Thallas V, Youssef S et al. Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia 1997 (in press).
57. Ferrara N, Houck K, Jakeman L, Leung D. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev. 1992; 13: 18-32.
58. Cooper ME, Gilbert RE, Allen TJ. Experimental diabetic nephropathy. In: Sima A (ed.). Lessons from animal diabetes VII. Elsevier, Amsterdam. 1997 (in press).
59. Rasch R. Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. Albumin excretion. Diabetologia 1980; 18: 413-16.
60. O'Brien RC, Cooper ME, Jerums G, Doyle AE. The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy. Diabetes 1993; 42: 604-9.
61. Zatz R, Dunn BR, Meyer TW, Brenner B. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 1986; 77: 1925-30.
62. Cooper ME, Allen TJ, O'Brien R, Clarke B, Jerums G, Doyle AE. Effects of genetic hypertension on diabetic nephropathy in the rat: Functional and structural characteristics. J. Hypertens. 1988; 6: 1009-16.
63. Kelly DJ, Berka JL, Allen T, Cooper ME, Skinner SL. The influence of amplified tissue renin on diabetic organ pathology in transgenic Ren-2 rats. J. Hypertens. 1996; 14 (Suppl.): S144.
64. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 344: 541-4.
65. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993; 329: 1456-62.